Danaher rises after quarterly profit beat

Life sciences firm Danaher's DHR.N shares rise 5% to $194.15

Posts Q1 adj. profit of $1.88 per share, beating analysts estimates of $1.64, according to data compiled by LSEG

Revenue of $5.74 billion also tops estimates of $5.59 billion

Anticipates Q2 revenue to grow low-single digits year-over-year

DHR expects annual profit in the range of $7.60 to $7.75 per share vs estimates of $7.68 per share; forecasts annual revenue to grow 3%

Expects to incur incremental tariff costs in 2025 of several hundred millions of dollars

Brokerage RBC Capital Markets says concerned that DHR did not account for a weaker economy in Q1, despite minimal issues from NIH spending, global tariffs, and a stock market decline that may impact spending by all university customers

Evercore ISI says DHR should hold up better vs peers as it expects the company to be immune to potential tariffs on pharma

As of last close, shares down 19.4% YTD